TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
1.1. Market Overview
1.2. Key Findings
1.3. Market Segmentation
1.4. Competitive Landscape
1.5. Challenges and Opportunities
1.6. Future Outlook
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the study
2.2.1. Research Objective
2.2.2. Assumption
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value chain Analysis
5.2. Porter's Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. NEUROPATHIC PAIN MARKET, BY DRUG CLASS (USD BILLION)
6.1. Antidepressants
6.2. Anticonvulsants
6.3. Topical Agents
6.4. Opioids
7. NEUROPATHIC PAIN MARKET, BY THERAPEUTIC AREA (USD BILLION)
7.1. Chronic Pain
7.2. Diabetic Neuropathy
7.3. Postherpetic Neuralgia
7.4. Multiple Sclerosis
8. NEUROPATHIC PAIN MARKET, BY ROUTE OF ADMINISTRATION (USD BILLION)
8.1. Oral
8.2. Transdermal
8.3. Intravenous
8.4. Topical
9. NEUROPATHIC PAIN MARKET, BY PATIENT TYPE (USD BILLION)
9.1. Adult
9.2. Geriatric
9.3. Pediatric
10. NEUROPATHIC PAIN MARKET, BY REGIONAL (USD BILLION)
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. UK
10.2.3. France
10.2.4. Russia
10.2.5. Italy
10.2.6. Spain
10.2.7. Rest of Europe
10.3. APAC
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Malaysia
10.3.6. Thailand
10.3.7. Indonesia
10.3.8. Rest of APAC
10.4. South America
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Argentina
10.4.4. Rest of South America
10.5. MEA
10.5.1. GCC Countries
10.5.2. South Africa
10.5.3. Rest of MEA
11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market share Analysis
11.4. Major Growth Strategy in the Neuropathic Pain Market
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Neuropathic Pain Market
11.7. Key developments and growth strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales and Operating Income
11.8.2. Major Players R&D Expenditure. 2023
12. COMPANY PROFILES
12.1. Catalent
12.1.1. Financial Overview
12.1.2. Products Offered
12.1.3. Key Developments
12.1.4. SWOT Analysis
12.1.5. Key Strategies
12.2. Eli Lilly
12.2.1. Financial Overview
12.2.2. Products Offered
12.2.3. Key Developments
12.2.4. SWOT Analysis
12.2.5. Key Strategies
12.3. GSK
12.3.1. Financial Overview
12.3.2. Products Offered
12.3.3. Key Developments
12.3.4. SWOT Analysis
12.3.5. Key Strategies
12.4. AbbVie
12.4.1. Financial Overview
12.4.2. Products Offered
12.4.3. Key Developments
12.4.4. SWOT Analysis
12.4.5. Key Strategies
12.5. Boehringer Ingelheim
12.5.1. Financial Overview
12.5.2. Products Offered
12.5.3. Key Developments
12.5.4. SWOT Analysis
12.5.5. Key Strategies
12.6. Teva Pharmaceutical Industries
12.6.1. Financial Overview
12.6.2. Products Offered
12.6.3. Key Developments
12.6.4. SWOT Analysis
12.6.5. Key Strategies
12.7. Horizon Therapeutics
12.7.1. Financial Overview
12.7.2. Products Offered
12.7.3. Key Developments
12.7.4. SWOT Analysis
12.7.5. Key Strategies
12.8. Lupin Pharmaceuticals
12.8.1. Financial Overview
12.8.2. Products Offered
12.8.3. Key Developments
12.8.4. SWOT Analysis
12.8.5. Key Strategies
12.9. Endo International
12.9.1. Financial Overview
12.9.2. Products Offered
12.9.3. Key Developments
12.9.4. SWOT Analysis
12.9.5. Key Strategies
12.10. Mallinckrodt Pharmaceuticals
12.10.1. Financial Overview
12.10.2. Products Offered
12.10.3. Key Developments
12.10.4. SWOT Analysis
12.10.5. Key Strategies
12.11. Johnson and Johnson
12.11.1. Financial Overview
12.11.2. Products Offered
12.11.3. Key Developments
12.11.4. SWOT Analysis
12.11.5. Key Strategies
12.12. Pfizer
12.12.1. Financial Overview
12.12.2. Products Offered
12.12.3. Key Developments
12.12.4. SWOT Analysis
12.12.5. Key Strategies
12.13. AstraZeneca
12.13.1. Financial Overview
12.13.2. Products Offered
12.13.3. Key Developments
12.13.4. SWOT Analysis
12.13.5. Key Strategies
12.14. Novartis
12.14.1. Financial Overview
12.14.2. Products Offered
12.14.3. Key Developments
12.14.4. SWOT Analysis
12.14.5. Key Strategies
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1. LIST OF ASSUMPTIONS
TABLE 2. NORTH AMERICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 3. NORTH AMERICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 4. NORTH AMERICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 5. NORTH AMERICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 6. NORTH AMERICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 7. US NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 8. US NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 9. US NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 10. US NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 11. US NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 12. CANADA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 13. CANADA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 14. CANADA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 15. CANADA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 16. CANADA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 17. EUROPE NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 18. EUROPE NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 19. EUROPE NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 20. EUROPE NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 21. EUROPE NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 22. GERMANY NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 23. GERMANY NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 24. GERMANY NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 25. GERMANY NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 26. GERMANY NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 27. UK NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 28. UK NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 29. UK NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 30. UK NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 31. UK NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 32. FRANCE NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 33. FRANCE NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 34. FRANCE NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 35. FRANCE NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 36. FRANCE NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 37. RUSSIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 38. RUSSIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 39. RUSSIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 40. RUSSIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 41. RUSSIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 42. ITALY NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 43. ITALY NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 44. ITALY NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 45. ITALY NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 46. ITALY NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 47. SPAIN NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 48. SPAIN NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 49. SPAIN NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 50. SPAIN NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 51. SPAIN NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 52. REST OF EUROPE NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 53. REST OF EUROPE NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 54. REST OF EUROPE NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 55. REST OF EUROPE NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 56. REST OF EUROPE NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 57. APAC NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 58. APAC NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 59. APAC NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 60. APAC NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 61. APAC NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 62. CHINA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 63. CHINA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 64. CHINA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 65. CHINA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 66. CHINA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 67. INDIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 68. INDIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 69. INDIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 70. INDIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 71. INDIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 72. JAPAN NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 73. JAPAN NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 74. JAPAN NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 75. JAPAN NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 76. JAPAN NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 77. SOUTH KOREA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 78. SOUTH KOREA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 79. SOUTH KOREA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 80. SOUTH KOREA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 81. SOUTH KOREA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 82. MALAYSIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 83. MALAYSIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 84. MALAYSIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 85. MALAYSIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 86. MALAYSIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 87. THAILAND NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 88. THAILAND NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 89. THAILAND NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 90. THAILAND NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 91. THAILAND NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 92. INDONESIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 93. INDONESIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 94. INDONESIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 95. INDONESIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 96. INDONESIA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 97. REST OF APAC NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 98. REST OF APAC NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 99. REST OF APAC NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 100. REST OF APAC NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 101. REST OF APAC NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 102. SOUTH AMERICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 103. SOUTH AMERICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 104. SOUTH AMERICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 105. SOUTH AMERICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 106. SOUTH AMERICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 107. BRAZIL NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 108. BRAZIL NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 109. BRAZIL NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 110. BRAZIL NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 111. BRAZIL NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 112. MEXICO NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 113. MEXICO NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 114. MEXICO NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 115. MEXICO NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 116. MEXICO NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 117. ARGENTINA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 118. ARGENTINA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 119. ARGENTINA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 120. ARGENTINA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 121. ARGENTINA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 122. REST OF SOUTH AMERICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 123. REST OF SOUTH AMERICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 124. REST OF SOUTH AMERICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 125. REST OF SOUTH AMERICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 126. REST OF SOUTH AMERICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 127. MEA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 128. MEA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 129. MEA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 130. MEA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 131. MEA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 132. GCC COUNTRIES NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 133. GCC COUNTRIES NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 134. GCC COUNTRIES NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 135. GCC COUNTRIES NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 136. GCC COUNTRIES NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 137. SOUTH AFRICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 138. SOUTH AFRICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 139. SOUTH AFRICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 140. SOUTH AFRICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 141. SOUTH AFRICA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 142. REST OF MEA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2032 (USD BILLIONS)
TABLE 143. REST OF MEA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)
TABLE 144. REST OF MEA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)
TABLE 145. REST OF MEA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY PATIENT TYPE, 2019-2032 (USD BILLIONS)
TABLE 146. REST OF MEA NEUROPATHIC PAIN MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 147. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
TABLE 148. ACQUISITION/PARTNERSHIP
LIST OF FIGURES
FIGURE 1. MARKET SYNOPSIS
FIGURE 2. NORTH AMERICA NEUROPATHIC PAIN MARKET ANALYSIS
FIGURE 3. US NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 4. US NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 5. US NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 6. US NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 7. US NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 8. CANADA NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 9. CANADA NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 10. CANADA NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 11. CANADA NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 12. CANADA NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 13. EUROPE NEUROPATHIC PAIN MARKET ANALYSIS
FIGURE 14. GERMANY NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 15. GERMANY NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 16. GERMANY NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 17. GERMANY NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 18. GERMANY NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 19. UK NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 20. UK NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 21. UK NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 22. UK NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 23. UK NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 24. FRANCE NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 25. FRANCE NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 26. FRANCE NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 27. FRANCE NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 28. FRANCE NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 29. RUSSIA NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 30. RUSSIA NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 31. RUSSIA NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 32. RUSSIA NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 33. RUSSIA NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 34. ITALY NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 35. ITALY NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 36. ITALY NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 37. ITALY NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 38. ITALY NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 39. SPAIN NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 40. SPAIN NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 41. SPAIN NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 42. SPAIN NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 43. SPAIN NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 44. REST OF EUROPE NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 45. REST OF EUROPE NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 46. REST OF EUROPE NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 47. REST OF EUROPE NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 48. REST OF EUROPE NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 49. APAC NEUROPATHIC PAIN MARKET ANALYSIS
FIGURE 50. CHINA NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 51. CHINA NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 52. CHINA NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 53. CHINA NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 54. CHINA NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 55. INDIA NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 56. INDIA NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 57. INDIA NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 58. INDIA NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 59. INDIA NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 60. JAPAN NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 61. JAPAN NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 62. JAPAN NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 63. JAPAN NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 64. JAPAN NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 65. SOUTH KOREA NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 66. SOUTH KOREA NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 67. SOUTH KOREA NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 68. SOUTH KOREA NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 69. SOUTH KOREA NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 70. MALAYSIA NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 71. MALAYSIA NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 72. MALAYSIA NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 73. MALAYSIA NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 74. MALAYSIA NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 75. THAILAND NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 76. THAILAND NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 77. THAILAND NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 78. THAILAND NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 79. THAILAND NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 80. INDONESIA NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 81. INDONESIA NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 82. INDONESIA NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 83. INDONESIA NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 84. INDONESIA NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 85. REST OF APAC NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 86. REST OF APAC NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 87. REST OF APAC NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 88. REST OF APAC NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 89. REST OF APAC NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 90. SOUTH AMERICA NEUROPATHIC PAIN MARKET ANALYSIS
FIGURE 91. BRAZIL NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 92. BRAZIL NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 93. BRAZIL NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 94. BRAZIL NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 95. BRAZIL NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 96. MEXICO NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 97. MEXICO NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 98. MEXICO NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 99. MEXICO NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 100. MEXICO NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 101. ARGENTINA NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 102. ARGENTINA NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 103. ARGENTINA NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 104. ARGENTINA NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 105. ARGENTINA NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 106. REST OF SOUTH AMERICA NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 107. REST OF SOUTH AMERICA NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 108. REST OF SOUTH AMERICA NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 109. REST OF SOUTH AMERICA NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 110. REST OF SOUTH AMERICA NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 111. MEA NEUROPATHIC PAIN MARKET ANALYSIS
FIGURE 112. GCC COUNTRIES NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 113. GCC COUNTRIES NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 114. GCC COUNTRIES NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 115. GCC COUNTRIES NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 116. GCC COUNTRIES NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 117. SOUTH AFRICA NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 118. SOUTH AFRICA NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 119. SOUTH AFRICA NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 120. SOUTH AFRICA NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 121. SOUTH AFRICA NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 122. REST OF MEA NEUROPATHIC PAIN MARKET ANALYSIS BY DRUG CLASS
FIGURE 123. REST OF MEA NEUROPATHIC PAIN MARKET ANALYSIS BY THERAPEUTIC AREA
FIGURE 124. REST OF MEA NEUROPATHIC PAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 125. REST OF MEA NEUROPATHIC PAIN MARKET ANALYSIS BY PATIENT TYPE
FIGURE 126. REST OF MEA NEUROPATHIC PAIN MARKET ANALYSIS BY REGIONAL
FIGURE 127. KEY BUYING CRITERIA OF NEUROPATHIC PAIN MARKET
FIGURE 128. RESEARCH PROCESS OF MRFR
FIGURE 129. DRO ANALYSIS OF NEUROPATHIC PAIN MARKET
FIGURE 130. DRIVERS IMPACT ANALYSIS: NEUROPATHIC PAIN MARKET
FIGURE 131. RESTRAINTS IMPACT ANALYSIS: NEUROPATHIC PAIN MARKET
FIGURE 132. SUPPLY / VALUE CHAIN: NEUROPATHIC PAIN MARKET
FIGURE 133. NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2024 (% SHARE)
FIGURE 134. NEUROPATHIC PAIN MARKET, BY DRUG CLASS, 2019 TO 2032 (USD Billions)
FIGURE 135. NEUROPATHIC PAIN MARKET, BY THERAPEUTIC AREA, 2024 (% SHARE)
FIGURE 136. NEUROPATHIC PAIN MARKET, BY THERAPEUTIC AREA, 2019 TO 2032 (USD Billions)
FIGURE 137. NEUROPATHIC PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
FIGURE 138. NEUROPATHIC PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019 TO 2032 (USD Billions)
FIGURE 139. NEUROPATHIC PAIN MARKET, BY PATIENT TYPE, 2024 (% SHARE)
FIGURE 140. NEUROPATHIC PAIN MARKET, BY PATIENT TYPE, 2019 TO 2032 (USD Billions)
FIGURE 141. NEUROPATHIC PAIN MARKET, BY REGIONAL, 2024 (% SHARE)
FIGURE 142. NEUROPATHIC PAIN MARKET, BY REGIONAL, 2019 TO 2032 (USD Billions)
FIGURE 143. BENCHMARKING OF MAJOR COMPETITORS
